Skip to content

LAM PEPFAR Request

  • Chad Cipiti

February 8, 2017: TAG and partner organizations advocating for the rights of people affected by HIV and TB around the world encouraged the President’s Emergency Plan for AIDS Relief (PEPFAR) to support the immediate introduction of the LAM test in all PEPFAR-funded…

Read more

Pre-CROI Community HIV Cure Research Workshop 2017

  • Chad Cipiti

On Sunday February 12, 2017 in Seattle, the AIDS Treatment Activists Coalition, AVAC, the DARE Community Advisory Board, the defeatHIV Community Advisory Board, European AIDS Treatment Group, Project Inform and TAG co-sponsored a community workshop on HIV cure research.

Read more

2016 TAG Update

  • Chad Cipiti

TAG's annual review of progress we've made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.

Read more

HIV Activists Seek to Accelerate Development of Immune Enhancing Therapies for Immunologic Non-Responders

  • Chad Cipiti

A coalition of HIV/AIDS activists are calling for renewed attention to HIV-positive people termed immunologic non-responders (INRs), who experience suboptimal immune system reconstitution despite years of viral load suppression by antiretroviral therapy. Studies have shown that INR patients remain at increased risk of illness and death compared to HIV-positive people who have better restoration of immune function on current drug therapies.

Read more

Story: Israeli Scientists See Breakthrough in AIDS Cure

  • Dorrit Walsh

November 2016 Examples of media coverage:  Israeli scientists see breakthrough in AIDS cure – The Times of Israel, November 1, 2016 Israeli researchers offer some hope for HIV carriers – Arutz Sheva 7, November 1, 2016 Israeli research successful in…

Read more

Reconsideration of support for impending 21st Century Cures Act

  • Chad Cipiti

Dear Minority Leader Pelosi: On behalf of Treatment Action Group (TAG), I write to you strongly urging for the reconsideration of your support for the passage of the 21st Century Cures Act. Even as an impending and new version of the bill is set to be introduced by Energy and Commerce Chairman, Rep. Fred Upton – we are concerned that several provisions carried from the prior iteration of the bill (H.R. 6) may continue to undermine public health and jeopardize patient safety. These concerns include lowering standards for the FDA in determining approval for prospective drugs and devices, increasing the likelihood of antimicrobial resistance, to granting extended market exclusivity for new drugs.

Read more
Back To Top